00:00It's Benzinga, bringing Wall Street to Main Street.
00:02Eli Lilly beat third quarter earnings and revenue estimates and raised its full year sales outlook
00:08as demand for diabetes and weight loss drugs surged, according to CNBC.
00:13Third quarter adjusted earnings came in at $7.48 per share on revenue of $24.40 billion,
00:21beating Wall Street expectations of $6.26 per share and $22.61 billion.
00:27The pharmaceutical giant raised its 2026 revenue outlook to $91 billion to $92 billion,
00:35from $85 billion to $87 billion.
00:39Munjaro sales jumped 65% to $10.72 billion, while ZepBound revenue climbed 49% to $5.35 billion.
00:50Both exceeded analyst estimates.
00:52However, sales of its newly launched obesity pill, Foundio, reached $184 million,
00:59missing expectations of $229 million.
01:03Lilly reported net income of $6.45 billion, up from $5.58 billion a year earlier.
01:11Shares rose about 4% in pre-market trading.
01:14For all things money, visit Benzinga.com.
Comments